Altimmune Stock Alpha and Beta Analysis
| ALT Stock | USD 3.86 0.12 3.02% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Altimmune. It also helps investors analyze the systematic and unsystematic risks associated with investing in Altimmune over a specified time horizon. Remember, high Altimmune's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Altimmune's market risk premium analysis include:
Beta 0.87 | Alpha 0.003049 | Risk 4.43 | Sharpe Ratio 0.0296 | Expected Return 0.13 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Altimmune | Build AI portfolio with Altimmune Stock |
Altimmune Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Altimmune market risk premium is the additional return an investor will receive from holding Altimmune long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Altimmune. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Altimmune's performance over market.| α | 0 | β | 0.87 |
Altimmune expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Altimmune's Buy-and-hold return. Our buy-and-hold chart shows how Altimmune performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Altimmune Market Price Analysis
Market price analysis indicators help investors to evaluate how Altimmune stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Altimmune shares will generate the highest return on investment. By understating and applying Altimmune stock market price indicators, traders can identify Altimmune position entry and exit signals to maximize returns.
Altimmune Return and Market Media
The median price of Altimmune for the period between Sun, Sep 28, 2025 and Sat, Dec 27, 2025 is 4.06 with a coefficient of variation of 12.96. The daily time series for the period is distributed with a sample standard deviation of 0.56, arithmetic mean of 4.36, and mean deviation of 0.49. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Vipin Garg of 26775 shares of Altimmune subject to Rule 16b-3 | 10/10/2025 |
2 | Acquisition by Vipin Garg of 18950 shares of Altimmune subject to Rule 16b-3 | 11/21/2025 |
3 | China Myopia Control Lenses Market Set to Hit Valuation of US 935.60 Million by 2033 Astute Analytica | 12/04/2025 |
4 | Disposition of 7231 shares by Vipin Garg of Altimmune at 6.64 subject to Rule 16b-3 | 12/05/2025 |
5 | Location Based Services Market Set to Reach US 547.92 Billion by 2033 as Breakthroughs in GNSS and RTK Precision Accelerate High-Accuracy Adoption Astute Analyt... | 12/08/2025 |
6 | Disposition of 11701 shares by Vipin Garg of Altimmune at 7.0 subject to Rule 16b-3 | 12/12/2025 |
7 | Thin-Film Electrode Market to Reach US 1,595.3 Million By 2035 Astute Analytica | 12/15/2025 |
8 | Fire Truck Market Set to Reach US 17.5 Billion by 2035 as Rising Municipal Capital Spending and Inflationary Pricing Drive Fleet Replacement Cycles Says Astute ... | 12/17/2025 |
9 | Vehicle to Grid Market Set to Reach US 65.84 Billion by 2035 Astute Analytica | 12/18/2025 |
10 | Altimmunes MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks | 12/19/2025 |
11 | Japan IT Services Market Valuation is Projected to Reach US 231.93 Billion By 2035 Astute Analytica | 12/22/2025 |
12 | Black Masterbatches Market Valuation to Surpass US 4,865.2 Million By 2035 Astute Analytica | 12/23/2025 |
About Altimmune Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Altimmune or other stocks. Alpha measures the amount that position in Altimmune has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | PTB Ratio | 4.14 | 4.35 | Dividend Yield | 26.32 | 23.4 |
Altimmune Upcoming Company Events
As portrayed in its financial statements, the presentation of Altimmune's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Altimmune's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Altimmune's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Altimmune. Please utilize our Beneish M Score to check the likelihood of Altimmune's management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Altimmune
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.